Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.


Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)

Asst. Prof. Shilpa Gupta discusses results from the Bladder Cancer Working Group survey study. The aim of the study is to define criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer (mUC). Platinum-ineligible mUC patients are those who are ineligible for cisplatin and carboplatin treatment and therefore have limited treatment options. Other treatments such as pembrolizumab and atezolizumab are available but restricted to patients who are either ‘platinum ineligible’ or who have high PD-L1 expression. Therefore, a definition of platinum-ineligibility is necessary when deciding on patient treatments, and for determining patients eligibility for clinical trials.

Methods for defining platinum ineligibility

Presented are data from two rounds of survey among genitourinary oncologists. The threshold of criteria such as age, ECOG performance status, creatinine clearance, peripheral neuropathy grade, and heart failure classification are assessed as possible defining factors for Platinum-Ineligibility. Prof. Gupta concludes 5 specified criteria, any one of which would class a patient as platinum-ineligible and thus receive immunotherapy in place of cisplatin and carboplatin. The video and slides aim to provide practical guidance for urologists and we hope you find it of use to your clinical practice.

Shilpa Gupta, MD is an Associate Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Prior to joining the University of Minnesota in July 2015, Dr Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for 4 years. Dr Gupta’s clinical and research interests are to treat patients with genitourinary malignancies and develop novel trials using targeted therapies and immunotherapies. She is currently the Principal investigator of several early and late phase trials in genitourinary oncology. Dr Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters. Twitter: @shilpaonc Email:guptash@umn.edu

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.